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Highlights 
 
 Hybrid peptides are research tools for GPCRs and their interacting complexes 
 Nine new ligands  were constructed from Dooley peptide RYYRIK and nociceptin  
fragments 
 Domain-like design (message/address) combines the features of the parent peptides 
 C-terminal amidation significantly effects the binding and pharmacological character 
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The endogenous ligand nociceptin (N/OFQ) and a positively charged synthetic peptide 
RYYRIK are both selective for the nociceptin opioid receptor (NOPr). Despite their structural 
dissimilarity, N/OFQ and RYYRIK compete for the same binding site of NOP receptor 
possessing full and partial agonistic character, respectively. In the view of the message-
address concept, hybrid peptide constructs were probed for the NOP receptor combining 
different regions of N/OFQ and RYYRIK related peptide sequences.  Nine novel nociceptin- 
or Ac-RYYRIK-NH2 peptide variants or hybrid peptides were synthesized and characterized. 
Peptides P2 and P8 contain fragments of native N/OFQ. The other seven analogues (P1, P3-7, 
P9) are composed of Ac-RYYRIK-NH2 fragments and parts of the original nociceptin 
sequence. The analogues were characterized in receptor binding assays and G-protein 
activation experiments on rat brain membranes, as well as by electrically stimulated mouse 
vas deferens bioassay. In receptor binding assays ligands P2 , P4 , P6 (Ki 0.37 nM) and P7 
showed higher affinity (Ki 0.65 nM, 0.6 nM, 0.37 nM and 0.44 nM, respectively) for NOP 
receptor than their parent compounds N/OFQ (Ki 2.8 nM) or Ac-RYYRIK-NH2 (Ki 4.2 nM). 
In [35S]GTPγS binding experiments P2 and P3 behaved as full agonists. The other variants 
exhibited partial agonist properties characterized by submaximal stimulatory effects. In 
mouse vas deferens bioassay only P2 showed agonist activity. P4, P5, P6 inhibited the 
biological activity of N/OFQ more effectively than the NOP receptor selective antagonist 
JTC-801. In summary, hybrid peptides P4, P5 and P6 proved to be NOP receptor partial 
agonists even antagonists, while P2 peptide retained the full agonist property. 
 
Keywords: opioid receptor, nociceptin, hybrid peptides, receptor binding,G-protein activation, 
mouse vas deferens bioassay, bivalent ligands 
 
Introduction 
The NOP receptor, belonging to the superfamily of G-protein-coupled receptors, was 
discovered in 1994, after the cloning of opioid-like orphan receptors [1,2]. It is well known 
that the N/OFQ-NOP receptor system is widely distributed throughout the nervous system and 
is involved in the modulation of numerous biological functions, such as pain, depression, 
reward, learning and memory, food intake, cardiovascular and kidney functions [3]. This 
multifunctionality of the N/OFQ-NOP receptor system makes NOP receptor a 
pharmacologically important target. NOP receptor agonists, antagonists and partial agonists 
may have  broad therapeutic potential for treating several disorders. Agonists could be useful 
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for treating drug addiction, anxiety, stress, cough and anorexia. Antagonists might be 
preferable for treating various pain states, depression and Parkinson’s disease. Partial agonists 
that behave as antagonists in the presence of a pure agonist are able to induce water diuresis 
[3].  
The natural endopeptide ligand of NOP receptor is the heptadecapeptide nociceptin or 
N/OFQ (FGGFTGARKSARKLANQ) [4-6]. The NOP receptor displays high homology with 
classical opioid receptors (MOP, DOP and KOP receptors), even though it is not able to bind 
to traditional opioid ligands and is not sensitive to naloxone in binding assays [2,7]. Being an 
endogenous ligand, N/OFQ binds to the NOP receptor with high affinity and activates it with 
good efficacy in biochemical experiments. Pharmacological properties of the 
heptadecapeptide N/OFQ are more complex, because pronociceptive and antinociceptive 
 effects were also described. N/OFQ was originally thought to increase a painful stimulus 
since intracerebroventricular (i.c.v.) injection of this peptide led to a decrease in tail-flick and 
hot-plate latency in mice. Further studies suggested that N/OFQ blocks opiate analgesia when 
administered i.c.v. but potentiates opiate analgesia and has antinociceptive activity when 
administered intrathecally [7]. The nociceptin ligand shows some homology with endogenous 
opioid peptides particularly dynorphin A, which is a KOP receptor selective agonist [8,9]. 
However, N/OFQ shows poor affinity for classical opioid receptors, which is attributed to its 
N-terminal residue Phe (instead of Tyr) [3]. This feature makes nociceptin highly selective for 
the NOP receptor over other opioid receptors.  
Therefore, structure–activity relationship (SAR) studies were performed on N/OFQ to 
identify the key chemical modifications of its sequence to enhance its potency, metabolic 
stability, yet modulate its agonist efficacy, which could lead to the development of effective 
pharmacophores [3,10]. These SAR studies revealed that the main pharmacological features 
of N/OFQ are retained in the N/OFQ (1-13) fragment and the role of the C-terminal 
tetrapeptide region (14-17) is negligible.  
Besides extensive studies of N/OFQ, screening a hexapeptide combinatorial library led 
to the identification of several positively hexapeptides with high affinity for the NOP receptor 
[11], of which Ac-RYYRIK-NH2, Ac-RYYRWK- NH2, Ac-RYYRWR-NH2, Ac-
RYYLWR-NH2 and Ac-RYYKWK-NH2 were investigated in further in vitro studies. 
Although these Dooley’s hexapeptides substantially differ in their sequence from nociceptin, 
they are also highly selective for the NOP receptor over the other opioid receptors behaving 
as partial agonists, antagonists or full agonist, depending on the tissue preparation or 
experimental conditions [12,13]. 
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Comparison of the sequences of N/OFQ and the hexapeptides points to a single 
common feature, namely all four basic residues of N/OFQ are comprised within a six residue 
long region (8-13) which, however, is far from the putative message region. Based on the fact 
that the hexapeptides and N/OFQ show very similar affinity and selectivity profiles, it seems 
obvious that these hexapeptides contain the message and address information within a 
significantly shorter fragment.  
It is known that the N-terminal sequence FGGF of N/OFQ binds deep in the 
transmembrane binding pocket of the NOP receptor [14], while the positively charged N/OFQ 
(8-13) binds the negatively charged ECL2 domain of NOP receptor [14], which has a critical 
role in receptor activation [14,15]. Molecular dynamics simulations suggest that N/OFQ (14-
17) does not interact with the NOP receptor [15]. This may be explained by the SAR studies, 
which show that the shortest active fragment of nociceptin is N/OFQ(1-13) [16,17]. 
It has been reported that Dooley's hexapeptides such as Ac-RYYRIK-NH2 competitively 
inhibited N/OFQ binding to the NOP receptor [18] and therefore their binding sites may 
overlap [19]. Since Ac-RYYRIK-NH2 contains basic amino acid residues, similarly to 
N/OFQ(8-13), it was assumed that this hexapeptide also bound to the acidic ECL2 [20]. 
However, Kawano et al found that Ac-RYYRIK-NH2 interacted with the receptor site to 
which nociceptin(1–7) or -(14–17) binds [19]. Akuzawa et al obtained similar results: they 
found that Ac-RYYRIK-NH2 and nociceptin(1-4) shared the NOP receptor binding pocket 
[21]. Bes and Meunier performed photoaffinity labeling studies using the photo-labile 
Dooley’s hexapeptide Ac-RYYRWR-NH2. Their results suggested that, contrary to the 
previously mentioned two hypotheses, these basic hexapeptides could bind to the TM2 
domain of NOP receptor, so N/OFQ and Ac-RYYRYK-NH2 did not share the binding sites on 
NOP receptor [20]. 
In this study nine new nociceptin analogues were constructed. Group 1 of these variants 
(consisting of 2 peptides denoted by P2 and P8) contained fragments of the natural nociceptin 
peptide, while Group 2 (7 ligands denoted by P1, P3, P4-7 and P9) included those analogues 
which were composed of Ac-RYYRIK and parts of the native nociceptin sequence. The 
hexapeptide motif RYYRIK was present at the N-terminus, the middle (P3) or the C-terminus 
(P9) of these chimeric peptide ligands.  
We hypothesized that the hybrid peptides in Group 2, which contain fragments of the 
N/OFQ sequence and RYYRIK may share the binding sites with nociceptin on the NOP 
receptor and bind to it with greater affinity than their parent peptides. Furthermore, we 
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assumed that those variants in Group 2 which carry Ac-RYYRIK at the N-terminus (P1, P4-
P7) could competitively inhibit N/OFQ in a highly selective manner.  
This paper is devoted to see whether the binding and receptor activation of the NOP 
receptor by novel synthetic peptide analoguess can be explained by modular interactions by 
combining the message and address regions of structurally distant peptide ligands.  Although 
an experimental design with all permutations of the supposed domains in NOP (plus 
RYYRIK and C-terminal amidation added) would supposedly serve more satisfactory answer 
using a fairly high number of peptides, present paper is addressing only certain key points in 
the modular building of active N/OFQ analogs.  It has been described that the truncated 
N/OFQ(1-13)-NH2 showed similar affinity and efficacy as the unmodified N/OFQ, which was 
explained as a consequence of the C-terminal amidation [22]. Therefore, we decided to 
amidate the C-terminus of some analogues (P1-4, P9), to test our hypothesis that this 
modification improves affinity and potency of these hybrid peptides. The present study aimed 
to characterize the pharmacological properties (affinity, selectivity and receptor preference) of 
the nine nociceptin peptide analogues in receptor binding and functional [35S]GTPS binding 
assays, as well as in mouse vas deferens bioassay. It is expected that hybrid sequences started 
with the Dooley’s motif (P1 and P4-7) will rather be possessing either partial agonist or 
antagonist properties. 
Materials and methods 
Radiochemicals 
[3H]nociceptin (specific activity: 115.5 Ci/mmol) was purchased from PerkinElmer 
(Boston, USA). [3H]HS-665 ([23]; s.a: 13.1 Ci/mmol), [3H]DAMGO (s.a: 38.8 Ci/mmol) and 
[3H]Ile5,6Deltorphin II ([24]; s.a: 19.6 Ci/mmol) were radiolabeled by the Laboratory of 
Chemical Biology group in BRC (Szeged, Hungary). Guanosine 5’-O--thio-[35S]-
triphosphate ([35S]GTPS; s.a: 1000 Ci/mmol) was purchased from Hartmann Analytic 
(Braunschweig, Germany).  
Peptides 
Nociceptin(1-17) and Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO) were obtained from 
Bachem Holding AG (Bubendorf, Switzerland). [D-Ala2,D -Leu5]enkephalin (DADLE) was 
purchased from Sigma-Aldrich (Budapest, Hungary). [Ile5,6]-Deltorphin II (IleDelt II) was 
synthetized in the laboratory of the Chemical Biology group of the Biological Research 
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Center (BRC), Szeged, Hungary. The novel peptides were prepared as follows: All solvents 
and coupling reagents were purchased from VWR (Radnor, PN, USA). Fmoc amino acids and 
Fmoc-Rink-amide MBHA resin (0.68 mmol/g) were purchased from Chem-Impex (Wood 
Dale, IL, USA) and IRIS Biotech GmbH (Marktredwitz, DH, Germany). Amino acids were 
used with orthogonal protecting groups as follows: OtBu for Tyr, Thr, Ser side chains, Pbf 
protecting group for Arg side chain, Boc protecting group for Lys side chain and Trt for Asn 
and Gln side chains [21]. The peptides were synthesized by Fmoc-SPPS (standard solid phase 
peptide synthesis) using TBTU/HOBt/DIPEA for coupling reactions and piperidine 20% 
solution in DMF for Fmoc group deprotection as previously described [22,23].  
Purification of the crude peptides were carried out by RP-HPLC using a Kromasil 100-
5C18, 4.6 mm x 250 mm, 5 micron column, at a flow rate of 4.0 mL/min and a linear gradient 
of H2O/acetonitrile/0.1% TFA ranging from 5% acetonitrile to 95% acetonitrile in 35 min.  
The purity of all final TFA salts was confirmed by analytical RP-HPLC (C18-4.6 
mmX250 mm, 5 micron column) at a flow rate of 1 mL/min, using eluent as a gradient of 
H2O/acetonitrile 0.1% TFA ranging from 15% acetonitrile to 45% acetonitrile in 12 min and 
was found to be ≥95%. The identity of final peptides was confirmed by ESI-LRMS. The mass 
spectrometry (MS) system consisted of an API 150EX, (Applied Biosystems) ion trap mass 
spectrometer (Foster City, CA) equipped with an electrospray ionization (ESI) source. The 
capillary temperature was set to 300 °C and the spray voltage to 4.00 kV. The fluid was 
nebulized using nitrogen (N2) as the sheath and auxiliary.  
Other chemicals 
Tris-HCl, MgCl2 x 6H2O, NaCl, EGTA and GTP analogue GTPS were purchased from 
Sigma-Aldrich (Budapest, Hungary). SB-612 and JTC-80 were purchased from Tocris 
Bioscience (Bristol, UK). Naloxone was kindly provided by the company Endo Laboratories 
DuPont de Nemours (Wilmington, DE, USA). The UltimaGoldTM MV aqueous scintillation 
cocktail was purchased from PerkinElmer (Boston, USA). 
Animals 
In in vitro receptor binding experiments we applied inbred Wistar rats (250-300 g body 
weight) which were housed in the local animal house of BRC (Szeged, Hungary), and male 
guinea pigs (~700 g body weight, LAL/HA/BR strain) which originated from LAB-ÁLL Bt. 
(Budapest, Hungary). In mouse vas deferens bioassay we used NMRI mice (35-45 g). Mice 
were purchased from Toxicoop (Budapest, Hungary) and were housed in the local animal 
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house of the Department of Pharmacology and Pharmacotherapy of the Semmelweis 
University (Budapest, Hungary). 
All animals were kept in groups of five in a temperature controlled room (21-24 oC) 
under a 12:12 light and dark cycle, allowed free access to tap water and standard rodent food 
until the time of sacrifice. The animals were handled humanely, in complete accordance with 
the European directive 2010/63/EU on the protection of animals used for scientific purposes 
and the Hungarian Act for the Protection of Animals in Research (XXVIII.tv. 32.§). Both the 
number of animals and their suffering were minimized throughout our experiments. 
Membrane preparation 
Preparation of rat brain membranes 
Throughout the in vitro receptor binding experiments we applied rat and guinea pig 
brain membranes. The membrane fractions were prepared according to the method described 
previously [24]. Briefly, the animals were decapitated and the brains were quickly removed. 
The brains without the cerebellum were homogenized in ice-cold 50 mM Tris–HCl buffer (pH 
7.4) using a Teflon-glass homogenizer. The filtered homogenates were centrifuged at 40,000 
× g for 20 min at 4 °C. Afterwards the pellet was resuspended in 50 mM Tris-HCl (pH 7.4) 
buffer and incubated at 37 °C for 30 min in a shaking water-bath. The centrifugation step was 
repeated after the incubation. The final pellet was suspended in 50 mM Tris-HCl (pH 7.4) 
buffer containing 0.32 M sucrose and stored at -85 °C until further use. 
Radioligand Binding Competition Experiments 
Aliquots of frozen rat and guinea pig brain membrane homogenates (40,000 x g, 20 
min, 4 °C) were centrifuged and washed to remove sucrose. The pellets were suspended in 50 
mM Tris-HCl buffer (pH 7.4) with up to 0.3-0.5 mg/ml of protein. Membranes were 
incubated with 1 nM of the radioligands and increasing concentrations (10-10-10-5 M) of the 
various unlabeled peptides to be tested. Incubation conditions depended on the radioligands: 
for [3H]DAMGO and [3H]Ile5,6Deltorphin II 35 °C for 45 min, for [3H]HS-665 30 °C for 45 
min, and for [3H]nociceptin 30 °C for 30 min. Guinea pig brain was used in those experiments 
in which the tested ligands were investigated for KOP receptor, because it has significantly 
more KOP receptors than rat brain. Total binding was measured in the presence of the given 
radioligands, while non-specific binding was determined in the presence of 10 µM of 
unlabeled naloxone, naltrindole, U-69,593 and nociceptin, respectively. After the incubation, 
the reaction was terminated by filtrating the samples through Whatman GF/C ([3H]DAMGO, 
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[3H]Ile5,6Deltorphin II or GF/B ([3H]U-69593 and [3H]nociceptin) glass fibre filters (GE 
Healthcare, Little Chalfont, UK) under vacuum (Brandel M24R Cell Harvester; Brandel 
Harvesters, Gaithersburg, MD). The filters were washed three times with 5 ml ice-cold 50 
mM Tris-HCl (pH 7.4) and then with UltimaGold MV aqueous scintillation cocktail (Perkin 
Elmer, Waltham, MA) to detect the radioactivity with a Packard Tricarb 2300TR LSC 
spectrometer. The competition binding assays were performed in duplicates and repeated at 
least three times. 
[35S]GTPγS Binding Experiments 
The functional [35S]GTPS binding assays were performed as described previously [25], 
with slight modifications. Rat and guinea pig brain membrane fractions (~10 μg of 
protein/sample) were incubated at 30 C for 60 min in Tris-EGTA buffer. The buffer 
contained 50 mM Tris-HCl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, 30 μM GDP, (pH 
7.4), as well as 20 MBq/0.05 cm3 [35S]GTPS (0.05 nM) and increasing concentrations (10-10 
– 10-5 M) of the tested nociceptin analogues and hybrid peptides. To investigate the NOP 
receptor selectivity 10 µM NOP receptor specific antagonist SB-612,111 was used. The final 
volume was 1 ml. Afterwards total binding (T) in the absence of the tested compounds was 
determined, and non-specific binding (NS) in the presence of 10 μM unlabeled GTPS to 
calculate basal activity.  
The reaction was terminated after incubation and bound and unbound [35S]GTPS were 
separated. The radioactivity of the filters was measured in the same way as described before. 
Isolated tissue assay 
Mouse vas deferens Bioassay 
Mouse vas deferens (NMRI mice, 35-45 g) was prepared as described before [26]. After 
the preparation vas deferens were suspended in 5 ml organ baths containing Mg2+ free Krebs 
buffer (118.1 mM NaCl, 25 mM NaHCO3, 4.7 mM KCl, 11 mM glucose, 1.2 mM KH2PO4, 
1.8 mM CaCl2) and aerated with carbogen (O2:CO2=95:5) at 31 C. The tissues were mounted 
between two electrodes under an initial tension of 0.1g. The stimulation parameters were as 
follows: field stimulation, pairs (100 ms pulse distance) of rectangular impulses (1 ms pulse 
width, 9V/cm i.e. supramaximal intensity) were repeated by 10 s. The muscle contractions 
were monitored by computer, using a data recording and the analysis system LabChart 5 
(ADInstruments Pty LTD, Australia). 
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Before adding the first dose of agonists, 30–40 min equilibration was performed on the 
tissues under stimulation. Then the cumulative concentration-response curves of to nociceptin 
analogues, hybrid peptides , nociceptin(1-17), or the control compounds were constructed.  
This method was suitable for separating peptides with agonist activity from peptides 
with antagonist activity. To determine the dissociation constants (Ke) of the antagonists,  
the single-dose method was used [27]. 
  
Data Analysis and Terminology 
All the experiments were repeated at least 3 times and the data were expressed as means 
± standard error of mean (S.E.M.) in logarithmic form. The radioligand competition binding 
experiments were performed in duplicates, while the [35S]GTPS binding assays were carried 
out in triplicates. The experimental data were analyzed and points were fitted with GraphPad 
Prism 6.0 (GraphPad Prism Software Inc., San Diego, CA, USA, www.graphpad.com) using 
non-linear regression. “One-site competition” was applied in the radioligand competition 
binding assays to determine unlabelled ligand affinity (IC50). In the [
35S]GTPS binding 
assays the ‘Sigmoid dose-response’ equation was used to determine ligand potency (EC50) 
and maximum G-protein efficacy (Emax). The curve fitting program outputs the logarithm of 
the standard errors of mean (S.E.M.) for IC50 and EC50 values, due to the data representation. 
The equilibrium inhibition constant (Ki) was calculated according to the Cheng-Prusoff 
equation: Ki= IC50/(1+[L]/Kd) [28] where IC50 is defined as the concentration of the 
competitor which produces 50% displacement, and [L] designates the concentration of the 
labelled ligand. Basal activity was determined in [35S]GTPS binding assays in the absence of 
receptor ligands, and was settled at 100%. The data were normalized to the basal activity. 
Agonist potencies were expressed as pEC50. The Emax is the maximal effect that an agonist 
can trigger in a given tissue or preparation. In the [35S]GTPγS binding assay Emax of agonists 
represents the maximal stimulation over the basal and it is expressed in %.  
After the analysis of experimental data from the MVD bioassay, EC50 were determined 
from individual logarithmic concentration-response curves. The equilibrium dissociation 
constant of antagonists (Ke) was calculated using the single-dose method [27]. Ke values were 
calculated with the following formula: Ke = concentration of antagonist/[dose ratio − 1] [29]. 
Unpaired t-test with two-tailed p-value was used to see the differences between the two data 
sets, while for three or more data sets one-way ANOVA with Tukey's post hoc test was 
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performed to determine statistical significance. Significance was accepted at the p < 0.05 
level. 
Results 
Receptor binding assays 
The sequences of the newly synthesized and characterized nociceptin analogues and 
nociceptin-RYYRIK hybrid peptides are summarized in Table 1, sorted into two groups: 
Group 1 consists of 2 ligands denoted as P2 and P8, which do not contain the RYYRIK motif, 
while Group 2 is comprised of 7 peptides denoted as P1, P3-7 and P9.  
In order to determine the NOP receptor binding affinity of the novel peptides 
radioligand competition binding assays were carried out with [3H]nociceptin on rat brain 
membranes. For control their parent compounds (nociceptin and Ac-RYYRIK-NH2) were 
also examined. 
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Table 1.  
List of fused hybrid peptides and their parent compounds with abbreviated names and 
sequences. 
Name/code  Length Sequence 
Parent peptides 
Nociceptin, N/OFQ 17 H-FGGFTGARKSARKLANQ-OH 
Dooley’s peptide 6 Ac-RYYRIK-NH2 
Group 1 (without RYYRIK) 
P2 17 H-FGGFTSARKGARKLANQ-NH2 
P8 11 H-FGGFGGGFGGF-NH2 
Group 2 (containing RYYRIK) 
P1 14 Ac-RYYRIKGARKLANQ-NH2 
P3 18 H-FGGFRYYRIKSARKLANQ-NH2 
P4 14 Ac-RYYRIKSARKLANQ-NH2 
P5 14 Ac-RYYRIKSARKLANQ-OH 
P6 18 Ac-RYYRIKGARKSARKLANQ-OH 
P7 14 Ac-RYYRIKGARKSARK-OH 
P9 13 H-FGGFGGGRYYRIK-NH2 
As shown in Fig. 1AB and Table 2, peptides P1-P7 competed more effectively for NOP 
receptor than P8 or P9, which showed negligible affinity towards NOP receptor.  
Surprisingly, P3 also showed low affinity in spite of FGGF being present at its N-
terminal. On the other hand, P1, P2, P4, P6 and P7 displayed higher affinity to NOP receptor 
compared to the parent compounds. Although P2 differs from nociceptin in that it contains 
Ser6 instead of Gly6, and Gly10 instead of Ser10, we observed a remarkable affinity (Ki=0.65) 
against [3H]nociceptin.  
The chimeric peptides possessing Ac-RYYRIK N-terminal were tested for KOP, MOP 
and DOP to reveal selectivity within the opioid receptor family. The results showed that none 
of the nociceptin-RYYRIK hybrid peptides displayed DOP receptor affinity (data not shown). 
However, [3H]DAMGO was almost fully displaced from its receptor by P4 in higher 
concentrations. P1 and P7 showed relatively high affinity in the MOP receptor binding (Ki=13 
and 209 nM) (data not shown). 
In competition binding assays performed with [3H]HS665, P4, P6 and P7 compounds 
fully displaced [3H]HS665 binding, however the inhibition was in the micromolar 
concentration range (data not shown).  
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Figure 1. NOP receptor binding affinity of nociceptin hybrid peptides (A and B) compared to 
nociceptin and Ac-RYYRIK-NH2 in [
3H]nociceptin competition binding assays in rat brain 
membrane homogenates. Figures represent the specific binding of [3H]nociceptin in 
percentage in the presence of increasing concentrations (10-10−10-5 M) of the indicated 
unlabeled ligands. The level of total specific binding was defined as 100% and points 
represent means  S.E.M. for at least three experiments performed in duplicates. 
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Table 2.  
Competition binding data of nociceptin hybrid peptides and their parent compounds in brain membrane homogenates. The logIC50 
values were calculated according to the competition binding curves (see Supplementary Figures 1 and 2). 
 Affinity, pIC50 ± S.E.M. (Ki, nM) 
Compounds [3H]HS665 
(KOP receptor) 
[3H]DAMGO 
(MOP receptor) 
[3H]nociceptin 
(NOP receptor) 
Parent compounds    
Nociceptin 9.34±2.9 (0.4) 8.26±0.33 (4.79) 8.5±0.1 (2.8) 
Ac-RYYRIK-NH2 6.22±1.1 (529) 7.3±3.2 (24.6) 8.4±2.5 (4.2) 
Fused hybrid peptides    
P1 Ac-RYYRIKGARKLANQ-NH2 5.8±0.5 (1482) 7.6±2.2 (26) 8.7±0.2 (2) 
P2 H-FGGFTSARKGARKLANQ-NH2 n.d. n.d. 9.1±0.1 (0.65) 
P3 H-FGGFRYYRIKSARKLANQ-NH2 n.d. n.d. 7.4±0.12 (36) 
P4 Ac-RYYRIKSARKLANQ-NH2 5.6±0.2 (2510) 5.3±0.4 (4549) 9.3±0.1 (0.6) 
P5 Ac-RYYRIKSARKLANQ-OH 5±0.7 (9699) 5.6±3.2 (2432) 8.3±0.1 (4.44) 
P6 Ac-RYYRIKGARKSARKLANQ-OH 5.5±0.2 (3202) 4.9±0.7 (12120) 9.4±0.2 (0.37) 
P7 Ac-RYYRIKGARKSARK-OH 5.4±0.3 (3998) 6.4±0.4 (422) 9.3±0.2 (0.44) 
P8 H-FGGFGGGFGGF-NH2 n.d. n.d. 4.2±2.2 (6192) 
P9 H-FGGFGGGRYYRIK-NH2 n.d. n.d. 6.9±0.3 (112) 
n.d.: not determined 
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[35S]GTPγS binding experiments 
 [35S]GTPγS binding experiments were performed on rat brain membranes to determine 
the potency (pEC50) and efficacy (Emax) of the nociceptin analogues and nociceptin-RYYRIK 
hybrid peptides. The test compounds were compared with their parent compounds, nociceptin, 
and Ac-RYYRIK-NH2. 
As it can be seen in Table 3 all the peptides moderately stimulated the monitored G-
protein except for P2 and P3. While P1, P4-P9 indicated partial agonist properties, P2 and P3 
exhibited full agonist activity similar to nociceptin (Emax: 157%, 152% and 148% for P2, P3 
and nociceptin, respectively). 
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Figure 2. [35S]GTPγS binding experiments in rat brain membranes. Panel A: stimulation of 
G-protein activation by nociceptin analogues. Panel B: nociceptin-RYYRIK hybrid peptides 
induced activation of G-proteins. Points represent means ± S.E.M. for at least three repeated 
experiments performed in triplicate.  
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Table 3. The stimulation of G-protein by the nociceptin hybrid peptides and their parent 
compounds in [35S]GTPS binding assays using rat brain membrane homogenates. The 
efficacy (Emax) and ligand potency (pEC50) values were calculated by analyzing dose-response 
binding curves. 
Peptides Rat brain membranes 
Potency 
 pEC50 ± S.E.M. (EC50, nM) 
Efficacy 
% Emax, ± S.E.M. 
Parent compounds  
Nociceptin 8.0±0.2 (9.2) 148±3.6 
Ac-RYYRIK-NH2 8.76±0.2 (2) 121±1.2 
Fused hybrid peptides  
P1 Ac-RYYRIKGARKLANQ-NH2 6.6±0.5 (258) 127±4.6 
P2 H-FGGFTSARKGARKLANQ-NH2 6.5±0.35 (338) 157±0.34 
P3 H-FGGFRYYRIKSARKLANQ-NH2 5.85±0.28 (1430) 152±8.2 
P4 Ac-RYYRIKSARKLANQ-NH2 6.9±0.41 (119) 119±3.65 
P5 Ac-RYYRIKSARKLANQ-OH 8.3±0.3 (5.4) 140±2.6 
P6 Ac-RYYRIKGARKSARKLANQ-OH 7.5±0.6 (147) 126±2.33 
P7 Ac-RYYRIKGARKSARK-OH 8.93±0.51 (1.2) 114±2.5 
P8 H-FGGFGGGFGGF-NH2 7.4±1.2 (44) 123±1.02 
P9 H-FGGFGGGRYYRIK-NH2 8.9±1.3 (1.3) 119±1.01 
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To reverse or inhibit the G-protein stimulatory effect of the test compounds, we applied NOP 
receptor specific antagonist SB612.111 in 10 µM concentrations (Fig.3). The stimulating 
effects of P2 and P3 were significantly antagonized by SB612.111, which confirms that NOP 
receptor is involved in mediating the effects of these peptides. 
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Figure 3. Effect of a nociceptin receptor specific antagonist ligand (SB-612,111) on the G-
protein activation by the nociceptin hybrid peptides. Columns shown represent mean values 
± S.E.M. SB-612,111 was used in 10 µM concentration. **p < 0.01 and ****p < 0.0001 vs. 
control group (unpaired t-test with Welch’s correction, two-tailed p-value). 
Mouse vas deferens bioassay 
The aim of the mouse vas deferens bioassay was the clarification the agonist or 
antagonist activity of the nociceptin analogues and nociceptin-RYYRIK hybrid peptides. As a 
first step we set out their ability of twitch response inhibition to electrical field stimulation 
without a NOP receptor antagonist to determine their agonistic activity. As detailed in Table 
4, the tested peptides showed slight inhibition only at high concentrations (i.e., 10 M) even 
in the case of P2. Although P2 displayed high affinity (Ki=0.65) for NOP receptor in 
radioligand competition binding assays and high efficacy (157%) in [35S]GTPγS binding 
experiments, we only observed weak affinity for P2 (426 nM) in comparison with nociceptin 
(62.4 nM) in mouse vas deferens bioassay. After characterizing the agonist activity of the 
tested peptides, we investigated their antagonist activity in the presence of nociceptin. The 
affinities of antagonists (Ke) are summarized in Table 4. P5 (Ke=136 nM, n=9), P6 (Ke=166 
nM, n=6) and P4 (Ke=258 nM, n=5) could antagonize the effect of nociceptin more 
effectively than the control antagonist JTC-801 (Ke=480 nM, n=11), which displayed a 
negligible partial agonist activity in high concentration (10 M) similar to P4, P5, P6 and P7.  
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Table 4. Effects of the nociceptin hybrid peptides and reference compounds on the 
electrically stimulated mouse vas deferens. 
Ligands EC50 (nM) ± 
S.E.M. 
Ke values for 
antagonists ± S.E.M. 
(nM) 
Control compounds   
Nociceptin 62±4 n.e. 
JTC-801 >100000 480±72 
Fused hybrid peptides   
P1 Ac-RYYRIKGARKLANQ-NH2 >10000 1943±341 
P2 H-FGGFTSARKGARKLANQ-NH2 426±76 n.e. 
P3 H-FGGFRYYRIKSARKLANQ-NH2 >1000000 n.e. 
P4 Ac-RYYRIKSARKLANQ-NH2 >100000 258±61 
P5 Ac-RYYRIKSARKLANQ-OH >1000000 136±26 
P6 Ac-RYYRIKGARKSARKLANQ-OH >100000 166±31 
P7 Ac-RYYRIKGARKSARK-OH >1000000 507±79 
P8 H-FGGFGGGFGGF-NH2 >1000000 n.e. 
P9 H-FGGFGGGRYYRIK-NH2 >1000000 n.e. 
n.e.: no effect 
Discussion 
The single natural ligand of the G-protein coupled NOP receptor, nociceptin (N/OFQ, 
FGGFTGARKSARKLANQ) was identified in 1995 via reverse pharmacology [3,4]. N/OFQ 
together with its NOP receptor forms the N/OFQ-NOP system, which has been intensively 
studied over the past 20 years. The investigations have revealed that both NOP receptor 
agonists and antagonists have significant therapeutic potential. Structure–activity relationship 
(SAR) studies were performed to identify those amino acids and/or sequences in the N/OFQ 
sequence that are essential for binding to and activation of NOP receptor. Furthermore, such 
chemical modifications were investigated that could increase potency, metabolic stability and 
agonist efficacy, or alter the agonist and antagonist properties.  
In this study 9 novel nociceptin variants were synthesized and characterized. Group 1 of 
these variants comprises peptides P2 and P8, which contain fragments of the natural 
nociceptin peptide. Group 2 includes those analogues (P1, P3, P4, P5, P6, P7, P9) which are 
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composed of the Ac-RYYRIK-NH2 hexapeptide and parts of the original nociceptin sequence. 
RYYRIK could be present at the beginning (N-terminal), the middle or the end (C-terminal) 
of these synthetic peptides. We chose Ac-RYYRIK-NH2 because it acted as an antagonist in 
the presence of nociceptin and inhibited its biological activity. 
Initially it was reported that transmembrane helix 2 of the NOP receptor takes part in 
the recognition of Ac-RYYRIK-NH2, but other molecular modelling and docking studies 
found that Ac-RYYRIK-NH2 interacts with those sits of NOP receptor such as N/OFQ, which 
implies that the binding sites of N/OFQ and RYYRIK may overlap. One of the implications 
of this result is that hybrid peptides from the combination of RYYRIK and parts of nociceptin 
may bind to NOP receptor with greater affinity than nociceptin itself. 
The 9 peptides were first studied in receptor binding assays. P8 (H-FGGFGGGFGGF-
NH2) and P2 (H-FGGFTSARKGARKLANQ-NH2) belonging to Group 1 had different 
affinities for the NOP receptor. While P8 was practically unable to displace [3H]nociceptin, 
the Ki value of P2 was lower than that of nociceptin. By synthesizing P8 our aim was to 
investigate whether we could create a high affinity peptide resembling little bit to biphalin 
[30]. However, the absence of the address domain resulted in a loss of binding ability 
probably because of the lack of some basic residues and other residues essential for binding. 
The sequences of P2 and N/OFQ are different, because N/OFQ contains the GARKSARK 
central motif, which is replaced with the SARKGARK sequence in P2, so the positions of the 
apolar Gly and the polar Ser have changed. A further difference is that P2 bears an amidated 
C-terminus.  In terms of binding affinity at the NOP receptor P2 proved to be the best peptide 
analogue among the compounds studied.  Similarly to the endogenous N/OFQ sequence, P2 
exhibited a full agonist profile (Emax 157%) although with lower potency in the [
35S]GTPγS 
binding experiments.  Beside N/OFQ, P2 was the other peptide carrying pure agonist activity 
in the mouse vas deferens bioassay.  Taken together, despite the three modifications, the 
biochemical and pharmacological properties of P2 and N/OFQ remained close to each other. 
The variants belonging to Group 2 (P1, P4, P5, P6 and P7) displaced [3H]nociceptin 
with high affinity. P4, P6 and P7 showed lower Ki values than even the parent peptides, 
indicating increased affinities. The cause of these high affinity values may well be that these 
peptides combine the favorable properties of RYYRIK and N/OFQ. Kawano et al. found that 
RYYRIK is likely to interact with the site of NOP receptor where nociceptin(1-7) and 
nociceptin(14-17) are involved [19]. Experimental results show that RYYRIK binds to the 
N/OFQ binding site with greater affinity than the original FGGF message domain, for which 
AC
CE
PT
ED
MA
NU
SC
RI
PT
19 
 
the Ac-RYY residues are primarily responsible. P4, P6 and P7 also contain the nociceptin 
address domain. Thus, by fusion of RYYRIK and N/OFQ, we could combine their beneficial 
properties that may have contributed to the increase of affinity.  
It is worth noting that although the amino acid sequences of P4 and P5 are identical, P4 
had a 7 times greater affinity (Ki =0.6 nM) than P5 (Ki =4 nM) towards the NOP receptor. 
This is explained by the fact that the C-terminus of P4 was amidated while that of P5 was not. 
It has already been shown that the truncated and amidated nociceptin(1-13)-NH2 exhibits a 
binding affinity and biological activity similar to the unmodified N/OFQ, in contrast with the 
deamidated truncated nociceptin(1-13), which showed poorer affinity and activity [22]. 
It was interesting to see that P1, which contains Gly7 instead of Ser7, displayed 30% 
lower Ki value than P4 toward the NOP receptor. We assume that the apolar Gly at position 7 
in the P1 ligand caused the reduction in affinity.  
Although it is well known that N/OFQ and RYYRIK bind selectively to the NOP 
receptor, we aimed to investigate whether hybrid peptides made of highly charged RYYRIK 
fused with portions of N/OFQ could retain their NOP receptor selectivity, since the sequence 
of nociceptin peptide exhibits some similarity with the endogenous KOP receptor selective 
dynorphin A, e.g. message domain, and many charged amino acids in the address domain.  
The results showed that the hybrid compounds had a weaker affinity for the KOP 
receptor than the parent compounds, so it could be excluded that hybridization of the two 
peptides could increase KOP receptor selectivity at the expense of NOP receptor selectivity.  
In [35S]GTPγS assays, P8 acted as a partial agonist, while the Emax value of P2 was 
higher than that of N/OFQ. It should be noted that while P2 had an EC50 of 338 nM (Table 3), 
the EC50 value of N/OFQ is 1.9 nM, i.e. N/OFQ is over 36x more potent as P2. Of note, drugs 
of high efficacy have advantage in therapy, because they are able to activate NOP receptor in 
pathological conditions where NOP receptor reserve is low. 
It has been demonstrated in case of N/OFQ that substituting the apolar - neutral Gly6 to 
Ala may slightly reduce the potency [10]. In the light of the fact that the potency has greatly 
decreased in our case, it is assumed that the replacement of the apolar amino acid with a more 
polar Ser6 was responsible for the large decrease. 
P4, P6 and P7 showed partial agonist activity while P5 was a full agonist in the G-
protein assay.  Of the five variants, the best EC50 was shown by P5 (1.2 nM) and P7 (5.4 nM). 
The Emax value of peptide P4 was 131 ± 0.42, while that of P5 was 140 ± 2.6. This contradicts 
our expectations, according to which P4 (which was amidated at the C-terminal end) was 
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expected to show full agonist activity. However, P4 showed lower potency and lower Emax 
(1028 nM) values as expected. Although P9 produced rather weak efficacy (Emax = 119 ± 
1.01), its potency was still strong. Conversely, P3 produced high Emax value with substantially 
weaker potency (1430 nM). We assume that this weak effect could have arisen from the 
insertion of the RYYRIK hexapeptide into the nociceptin sequence. The role of the positively 
charged segment was addressed by peptides P3 and P9: In P9 the N-terminal FGGF (essential 
in N/OFQ) was connected to RYYRIK by the GGG spacer positioning the first Arg residue to 
the same place where N/OFQ holds the first Arg residue (Arg8). At a time the minimal active 
length of 13 (in N/OFQ) was kept. The very week affinity of the resulting peptide, however, 
points to the importance of sequence specific interactions rather than to the position of the 
charged segment. P3 showed somewhat higher affinity, presumably due to the presence of the 
natural address region (in a more or less the correct distance from the N-terminal) and the 
Arg8 residue essential in N/OFQ. 
Variants that showed full agonist activity (P2, P3, P5) in the G-protein assay, were also 
tested for NOP receptor selectivity. To achieve this, an effective NOP receptor selective 
antagonist, SB612, was used. The Fig. 3 clearly shows that the Emax of P2, P3 and P5 were 
decreased in the presence of the antagonist. This demonstrates that our hybrid peptide ligands 
affected NOP receptor in a selective way.  
Following in vitro biochemical studies, the pharmacological effects of the peptide 
variants were also investigated in mouse vas deferens bioassay. First, the ligands were tested 
alone to determine their agonist potency and efficacy. The studied ligands did not exhibit 
agonist activity, except for P2, in the case of which the EC50 was 426 ± 76 nM, while it was 
over 10 μM for all other peptides. 
This result is surprising because the ligands proved to be promising in both binding and 
[35S]GTPγS tests based on the Ki, EC50 and Emax values. Apart from this, the peptides are 
considered worthy of further investigations. Furthermore, it is important to note that, although 
P3 was also expected to achieve better agonist activity based on its Emax value (which was 
better than that of N/OFQ), despite our expectations, this ligand was inactive in the bioassay. 
Only those ligands were expected to have antagonistic activity that contained RYYRIK 
at their N-terminal because RYYRIK itself acted as antagonist in previous [35S]GTPγS and 
mouse vas deferens experiments. Our results confirmed these expectations, as partial agonist 
ligands that did not contain RYYRIK, or did contain RYYRIK but not at their N-terminus 
(P9), proved to be inactive.  P8 and P9 were found to be partial agonists in the [35S]GTPγS 
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binding experiments, but they were completely inactive in the mouse vas deferens bioassay. 
In the radioligand binding studies only P9 exhibited a relatively high affinity, while P8 
bearing two FGGF tandem ‘message’ motifs was practically inactive (Ki > 6 µM).  One of the 
longest hybrid octadecapeptide variants P3 also showed high affinity in competition binding 
assays and high efficacy in [35S]GTPγS binding tests, but it was fully inactive in mouse vas 
deferens bioassay.  These findings suggest that the use of a diversified experimental approach 
is better in characterizing novel synthetic analogues with previously unknown properties. 
Summarizing the results, those ligands have been shown to be the most potent 
antagonists that carry RYYRIK on the N-terminus. These results suggest that the binding sites 
of RYYRIK and nociceptin on NOP receptor may overlap. However, it cannot be ruled out 
that RYYRIK binds to the NOP receptor at the TM2 domain. For P2 it can be established that, 
although it bound to NOP receptor with greater affinity than N/OFQ, and its Emax value was 
also greater than that of nociceptin, its EC50 was lower in both GTP and MVD tests than the 
EC50 of nociceptin (36 times and 7 times, respectively). It is worth mentioning that, despite 
the fact that P5 performed worse than P4 in the binding tests, the receptor activity test showed 
full agonist activity, and its potency was 190 times higher than that of P4. The mouse vas 
deferens bioassay also showed that P5 acts as a more effective antagonist than P4. This 
contradicts our hypothesis that the amidation of the C-terminus increases the affinity and 
biological activity of N/OFQ peptide analogues. The present data demonstrated that only one 
of our experimentally studied peptides, P2 retained the full agonist property, while those 
hybrids which contain the Dooley’s sequence at their N-terminal (P1 and P4-7) exhibited 
partial agonism with significant antagonist activity. Ultimately, it would be useful to further 
investigate these peptides in in vivo experiments as well.  
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